BR112017009728A2 - anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio - Google Patents
anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbioInfo
- Publication number
- BR112017009728A2 BR112017009728A2 BR112017009728-1A BR112017009728A BR112017009728A2 BR 112017009728 A2 BR112017009728 A2 BR 112017009728A2 BR 112017009728 A BR112017009728 A BR 112017009728A BR 112017009728 A2 BR112017009728 A2 BR 112017009728A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- methods
- disorder
- vector
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
a invenção fornece anticorpos de interleucina-33 (il-33) e métodos de uso dos mesmos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462077876P | 2014-11-10 | 2014-11-10 | |
US62/077,876 | 2014-11-10 | ||
US201562165732P | 2015-05-22 | 2015-05-22 | |
US62/165,732 | 2015-05-22 | ||
PCT/US2015/060008 WO2016077381A1 (en) | 2014-11-10 | 2015-11-10 | Anti-interleukin-33 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017009728A2 true BR112017009728A2 (pt) | 2018-02-06 |
Family
ID=54608970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017009728-1A BR112017009728A2 (pt) | 2014-11-10 | 2015-11-10 | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio |
Country Status (19)
Country | Link |
---|---|
US (3) | US10093730B2 (pt) |
EP (2) | EP3783023A1 (pt) |
JP (1) | JP6929771B2 (pt) |
KR (1) | KR20170080604A (pt) |
CN (1) | CN107172879B (pt) |
AU (1) | AU2015346460A1 (pt) |
BR (1) | BR112017009728A2 (pt) |
CA (1) | CA2960297A1 (pt) |
CO (1) | CO2017005650A2 (pt) |
CR (1) | CR20170240A (pt) |
EA (1) | EA201791029A1 (pt) |
HK (1) | HK1243440A1 (pt) |
IL (1) | IL251248A0 (pt) |
MX (1) | MX2017006094A (pt) |
PE (1) | PE20170910A1 (pt) |
PH (1) | PH12017500861A1 (pt) |
SG (1) | SG11201703767XA (pt) |
TW (1) | TWI705976B (pt) |
WO (1) | WO2016077381A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013188316A1 (en) * | 2012-06-11 | 2013-12-19 | Avalanche Biotechnologies, Inc. | Optical regulation of gene expression in the retina |
EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | 抗インターロイキン−33抗体及びその使用 |
JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック, インコーポレイテッド | Il-33媒介性障害のための治療及び診断方法 |
CN108137681A (zh) | 2015-09-23 | 2018-06-08 | 豪夫迈·罗氏有限公司 | 抗-vegf抗体的优化的变体 |
WO2017187307A1 (en) | 2016-04-27 | 2017-11-02 | Pfizer Inc. | Anti-il-33 antibodies, compositions, methods and uses thereof |
US20190225682A1 (en) * | 2016-09-02 | 2019-07-25 | 180 Therapeutics Lp | Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody |
WO2018045213A1 (en) * | 2016-09-02 | 2018-03-08 | 180 Therapeutics Lp | Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody |
JOP20190093A1 (ar) * | 2016-10-28 | 2019-04-25 | Lilly Co Eli | أجسام مضادة لـ il-33 واستخداماتها |
TW202332696A (zh) | 2016-12-01 | 2023-08-16 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
MX2019009485A (es) | 2017-02-10 | 2019-11-05 | Genentech Inc | Anticuerpos contra triptasa, composiciones de estos y usos de estos. |
AU2018252974A1 (en) | 2017-04-13 | 2019-11-28 | Regeneron Pharmaceuticals, Inc. | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1 |
JP2020527332A (ja) | 2017-06-12 | 2020-09-10 | ブルーフィン バイオメディシン, インコーポレイテッド | 抗−il1rap抗体および抗体薬物コンジュゲート |
CN111787947A (zh) | 2018-02-09 | 2020-10-16 | 豪夫迈·罗氏有限公司 | 用于肥大细胞介导的炎性疾病的治疗和诊断方法 |
IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantification of IL-33 |
CN108795934B (zh) * | 2018-05-23 | 2022-06-21 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 日本血吸虫SjELAV-like 2基因的siRNA及其应用 |
CN110551745A (zh) * | 2018-05-31 | 2019-12-10 | 康码(上海)生物科技有限公司 | 一种多重组氨酸序列标签及其在蛋白质表达、纯化中的应用 |
TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | 抗il1rap抗體及其使用方法 |
CN113260626A (zh) | 2018-11-05 | 2021-08-13 | 豪夫迈·罗氏有限公司 | 在原核宿主细胞中产生双链蛋白质的方法 |
CA3158323A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Methods of using il-33 antagonists |
WO2021089559A1 (en) | 2019-11-04 | 2021-05-14 | Medimmune Limited | Anti il-33 therapeutic agent fpr treating renal disorders |
BR112022018254A2 (pt) | 2020-03-13 | 2022-10-25 | Genentech Inc | Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo |
CN115315527A (zh) | 2020-03-13 | 2022-11-08 | 免疫医疗有限公司 | 用于治疗il33中存在风险等位基因的受试者的治疗方法 |
BR112022019937A2 (pt) | 2020-04-06 | 2022-12-13 | Medimmune Ltd | Tratamento de síndrome do desconforto respiratório agudo com antagonistas de ligação de eixo de il-33 |
CN115551542A (zh) | 2020-05-11 | 2022-12-30 | 免疫医疗有限公司 | 抗il-33抗体的配制品 |
CN111378037B (zh) * | 2020-06-01 | 2020-09-01 | 南京诺艾新生物技术有限公司 | 一种抗hIL-33人源化单抗及其应用 |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
WO2023166418A2 (en) * | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
WO2023178265A2 (en) * | 2022-03-18 | 2023-09-21 | Novascope Biochips Inc. | Antibody for porcine reproductive and respiratory syndrome virus and uses thereof |
TW202402790A (zh) | 2022-03-25 | 2024-01-16 | 英商梅迪繆思有限公司 | 減少呼吸系統感染之方法 |
WO2024038185A1 (en) | 2022-08-19 | 2024-02-22 | Medimmune Limited | Method of selecting patients for treatment with an il-33 axis antagonist |
Family Cites Families (192)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2 Inc | Geänderte antikörper. |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
ES2173873T5 (es) | 1992-10-28 | 2007-03-01 | Genentech, Inc. | Utilizacion de anticuerpos anti-vegf para el tratamiento del cancer. |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
WO1998058964A1 (en) | 1997-06-24 | 1998-12-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
EP2261229A3 (en) | 1998-04-20 | 2011-03-23 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
JP2003512019A (ja) | 1999-01-15 | 2003-04-02 | ジェネンテック・インコーポレーテッド | 変化したエフェクター機能を有するポリペプチド変異体 |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
MXPA02003456A (es) | 1999-10-04 | 2002-10-23 | Medicago Inc | Metodo para regular la transcripcion de genes foraneos. |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
WO2001044463A1 (en) | 1999-12-15 | 2001-06-21 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
WO2001070817A1 (fr) | 2000-03-21 | 2001-09-27 | Medical & Biological Laboratories Co., Ltd. | Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant |
DE60139189D1 (de) | 2000-03-23 | 2009-08-20 | Genentech Inc | Anti-c2/c2a inhibitoren zur komplement aktivierung |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES |
ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
WO2003085119A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
AU2003239966B9 (en) | 2002-06-03 | 2010-08-26 | Genentech, Inc. | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
WO2004056868A2 (en) | 2002-12-19 | 2004-07-08 | Endocube Sas | Nf-hev compositions and methods of use |
EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
KR20120104408A (ko) | 2003-05-30 | 2012-09-20 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
HUE031632T2 (en) | 2003-11-05 | 2017-07-28 | Roche Glycart Ag | Antigen binding molecules with enhanced Fc receptor binding affinity and effector function |
BR122018071808B8 (pt) | 2003-11-06 | 2020-06-30 | Seattle Genetics Inc | conjugado |
JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
CN104013957B (zh) | 2003-12-23 | 2016-06-29 | 泰勒公司 | 用新的抗il13单克隆抗体治疗癌症 |
NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
EP2360186B1 (en) | 2004-04-13 | 2017-08-30 | F. Hoffmann-La Roche AG | Anti-P-selectin antibodies |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
DK2500030T4 (en) | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
US8187569B2 (en) | 2006-02-14 | 2012-05-29 | Exxonmobil Chemical Patents Inc. | Process for manufacturing molecular sieve of MFS framework type and its use |
ATE527544T1 (de) | 2006-04-24 | 2011-10-15 | Critical Care Diagnostics Inc | Vorhersage von letalität und detektion von schweren erkrankungen |
EP2021799B1 (en) | 2006-04-27 | 2011-07-20 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
PL2019965T3 (pl) | 2006-05-02 | 2015-10-30 | Critical Care Diagnostics Inc | Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego |
WO2007130627A2 (en) | 2006-05-04 | 2007-11-15 | The Brigham And Women's Hospital, Inc. | Il-33 in the treatment and diagnosis of diseases and disorders |
TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
US8865645B2 (en) | 2006-05-24 | 2014-10-21 | Biogen Idec Ma Inc. | Method of treating lung fibrosis using ST2 polypeptide |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
SE532250C2 (sv) | 2006-11-28 | 2009-11-24 | Theravac Pharmaceuticals Ab | Nya formuleringar av IL-33 för behandling av inflammatoriska tillstånd med en stark TH2 komponent genom vaccinering |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
IE20080331A1 (en) | 2007-04-26 | 2009-07-08 | Trinity College Dublin | Products for altering cytokine activity and methods therefor |
AU2008254704A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | IL-33 in inflammatory disease |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
US20100310575A1 (en) | 2007-10-26 | 2010-12-09 | Max-Planck-Gesellschaft Zur Forderung Der Wissensc | Inhibitors of Caspase I-Dependent Cytokines in the Treatment of Neurodegenerative Disorders |
US8592562B2 (en) | 2008-01-07 | 2013-11-26 | Amgen Inc. | Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects |
WO2009145810A2 (en) | 2008-01-08 | 2009-12-03 | University Of Massachusetts Medical School | St2-based dengue fever diagnostic |
US20110044894A1 (en) | 2008-03-26 | 2011-02-24 | Cellerant Therapeutics, Inc. | Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof |
US8349322B2 (en) | 2008-06-25 | 2013-01-08 | ESBATech, an Alcon Biomedical Research Unit, LLC | Stable and soluble antibodies inhibiting VEGF |
CA2749966A1 (en) | 2009-01-29 | 2010-08-05 | Abbott Laboratories | Il-1 binding proteins |
US20110165063A1 (en) | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
EP2772269A3 (en) | 2009-03-05 | 2015-01-14 | Abbvie Inc. | IL-17 binding proteins |
JP5428422B2 (ja) | 2009-03-17 | 2014-02-26 | ヤマハ株式会社 | 電子楽器 |
US20120263709A1 (en) | 2009-09-10 | 2012-10-18 | Schering Corporation | Use of il-33 antagonists to treat fibrotic diseases |
BR112012007365A2 (pt) | 2009-10-15 | 2016-11-22 | Abbott Lab | proteínas de ligação à il-1 |
TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
JP6048972B2 (ja) | 2010-04-23 | 2016-12-21 | ジェネンテック, インコーポレイテッド | ヘテロ多量体タンパク質の産生 |
HUE033063T2 (hu) | 2010-05-14 | 2017-11-28 | Abbvie Inc | IL-1 kötõ fehérjék |
KR20130092589A (ko) | 2010-10-29 | 2013-08-20 | 에프. 호프만-라 로슈 아게 | Il33 n―말단 도메인 결실을 갖는 염증의 쥣과 모델 |
CA3040095C (en) | 2010-12-16 | 2021-09-07 | Genentech, Inc. | Diagnosis and treatments relating to th2 inhibition |
WO2012088094A2 (en) | 2010-12-21 | 2012-06-28 | Abbott Laboratories | Il-1 binding proteins |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
ES2549637T3 (es) * | 2011-02-23 | 2015-10-30 | F. Hoffmann-La Roche Ag | Anticuerpos contra IL33R humano y la utilización de los mismos |
FR2972006B1 (fr) | 2011-02-24 | 2016-03-25 | Centre Nat Rech Scient | Nouveaux fragments d'il-33 superactifs et leurs utilisations |
EP2699671B1 (en) | 2011-04-21 | 2019-07-10 | The Rockefeller University | Anti-inflammatory agents |
BR112014001283A2 (pt) | 2011-07-18 | 2017-02-21 | Critical Care Diagnostics Inc | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício |
AU2012288846B2 (en) | 2011-07-27 | 2016-05-19 | Glaxo Group Limited | Anti-VEGF single variable domains fused to fc domains |
ES2687951T3 (es) | 2011-10-14 | 2018-10-30 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HtrA1 y procedimientos de uso |
US9090694B2 (en) | 2012-04-30 | 2015-07-28 | Janssen Biotech, Inc. | ST2L antibody antagonists |
UY34813A (es) | 2012-05-18 | 2013-11-29 | Amgen Inc | Proteínas de unión a antígeno dirigidas contra el receptor st2 |
MX358541B (es) | 2012-08-16 | 2018-08-24 | Critical Care Diagnostics Inc | Metodos para predecir el riesgo de desarrollar hipertension. |
US20150250808A1 (en) | 2012-10-15 | 2015-09-10 | Vojo P. Deretic | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
US20150259645A1 (en) | 2012-11-08 | 2015-09-17 | INSERM (Institut National de la Santé et de la Recherche Médicale | Method for inducing il-2-free proliferation of gamma delta t cells |
WO2014090800A1 (en) | 2012-12-10 | 2014-06-19 | Vib Vzw | Novel interleukin-33 inhibitors |
WO2014126277A1 (ko) | 2013-02-14 | 2014-08-21 | 건국대학교 산학협력단 | 신규한 인터루킨-33 수용체와 결합 단백질 조성물 및 그 용도 |
WO2014128254A1 (en) | 2013-02-22 | 2014-08-28 | University Of Eastern Finland (Kuopion Kampus) | Il-33 and treatment of neurodegenerative diseases |
JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
US9637535B2 (en) | 2013-03-15 | 2017-05-02 | Regeneron Pharmaceuticals, Inc. | IL-33 antagonists and uses thereof |
US9949465B2 (en) | 2013-05-01 | 2018-04-24 | Hyogo College Of Medicine | Atopic dermatitis model animal and use thereof |
WO2015042521A1 (en) | 2013-09-20 | 2015-03-26 | University Of Virginia Patent Foundation | Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders |
CN111012905B (zh) | 2013-10-07 | 2023-12-22 | 宾夕法尼亚大学理事会 | 具有作为佐剂的白介素-33的疫苗 |
RU2016119425A (ru) | 2013-10-23 | 2017-11-28 | Дженентек, Инк. | Способы диагностики и лечения эозинофильных заболеваний |
WO2015077888A1 (en) | 2013-11-28 | 2015-06-04 | University Of Manitoba | Idr peptide compositions and use thereof for treatment of th2-dysregulated inflammatory conditions |
JP6159419B2 (ja) | 2013-12-26 | 2017-07-05 | 田辺三菱製薬株式会社 | ヒト抗il−33中和モノクローナル抗体 |
EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
WO2015143343A2 (en) | 2014-03-21 | 2015-09-24 | The Brigham And Women's Hospital, Inc. | Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring |
EP3134120B1 (en) | 2014-04-21 | 2024-01-24 | The Children's Hospital of Philadelphia | Compositions and methods for treating cytokine-related disorders |
DK3149049T3 (da) | 2014-05-27 | 2023-01-23 | Univ Queensland | Il-22 til anvendelse til behandling af stofskiftesygdomme |
GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
US20160145344A1 (en) | 2014-10-20 | 2016-05-26 | University Of Southern California | Murine and human innate lymphoid cells and lung inflammation |
JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック, インコーポレイテッド | Il-33媒介性障害のための治療及び診断方法 |
JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック, インコーポレイテッド | 抗インターロイキン−33抗体及びその使用 |
US11137397B2 (en) | 2014-11-24 | 2021-10-05 | Albert Einstein College Of Medicine | Peptides for blocking IL1RAP protein-protein interaction and uses thereof for treatment of disease |
US20170360907A1 (en) | 2014-12-04 | 2017-12-21 | The University Of North Carolina At Chapel Hill | Compositions and methods for preventing and treating graft versus host disease |
WO2016122865A1 (en) | 2015-01-30 | 2016-08-04 | Salk Institute For Biological Studies | Compositions and methods for treating age-related diabetes and related disorders |
US10500273B2 (en) | 2015-03-02 | 2019-12-10 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an IL-33 antagonist |
CA3015392A1 (en) | 2015-03-03 | 2016-09-09 | Wilfred Jefferies | Modulation of cancer immunity with type 2 innate lymphoid cells, interleukin 33, and/or interferon induced protein 44 |
AU2016233398A1 (en) | 2015-03-16 | 2017-09-07 | F. Hoffmann-La Roche Ag | Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases |
NZ736026A (en) | 2015-03-31 | 2023-02-24 | Medimmune Ltd | A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same |
CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
EP3331551B1 (en) | 2015-07-10 | 2021-06-23 | The Hong Kong University of Science and Technology | Compositions for use in treating neurodegenerative and neuroinflammatory conditions |
CL2015002153A1 (es) | 2015-07-31 | 2016-01-29 | Pontificia Universidad Católica De Chile | Uso de los marcadores moleculares il-3,il33 e il-12p40 para caracterizar la severidad de infecciones respiratorias por virus respiratorio sincicial y metapneumovirus humano |
EA201890891A1 (ru) | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
WO2017187307A1 (en) | 2016-04-27 | 2017-11-02 | Pfizer Inc. | Anti-il-33 antibodies, compositions, methods and uses thereof |
-
2015
- 2015-11-10 JP JP2017525046A patent/JP6929771B2/ja active Active
- 2015-11-10 EP EP20167906.5A patent/EP3783023A1/en not_active Withdrawn
- 2015-11-10 MX MX2017006094A patent/MX2017006094A/es unknown
- 2015-11-10 KR KR1020177012891A patent/KR20170080604A/ko unknown
- 2015-11-10 EP EP15797767.9A patent/EP3218403B1/en active Active
- 2015-11-10 EA EA201791029A patent/EA201791029A1/ru unknown
- 2015-11-10 PE PE2017000823A patent/PE20170910A1/es unknown
- 2015-11-10 BR BR112017009728-1A patent/BR112017009728A2/pt not_active Application Discontinuation
- 2015-11-10 SG SG11201703767XA patent/SG11201703767XA/en unknown
- 2015-11-10 CA CA2960297A patent/CA2960297A1/en not_active Abandoned
- 2015-11-10 TW TW104137071A patent/TWI705976B/zh not_active IP Right Cessation
- 2015-11-10 AU AU2015346460A patent/AU2015346460A1/en not_active Abandoned
- 2015-11-10 CN CN201580072740.9A patent/CN107172879B/zh active Active
- 2015-11-10 US US14/937,778 patent/US10093730B2/en active Active
- 2015-11-10 WO PCT/US2015/060008 patent/WO2016077381A1/en active Application Filing
- 2015-11-10 CR CR20170240A patent/CR20170240A/es unknown
-
2017
- 2017-03-19 IL IL251248A patent/IL251248A0/en unknown
- 2017-05-09 PH PH12017500861A patent/PH12017500861A1/en unknown
- 2017-06-07 CO CONC2017/0005650A patent/CO2017005650A2/es unknown
-
2018
- 2018-03-01 HK HK18102986.2A patent/HK1243440A1/zh unknown
- 2018-08-31 US US16/119,667 patent/US10723795B2/en active Active
-
2020
- 2020-06-16 US US16/903,300 patent/US11725050B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN107172879A (zh) | 2017-09-15 |
EP3218403A1 (en) | 2017-09-20 |
HK1243440A1 (zh) | 2018-07-13 |
KR20170080604A (ko) | 2017-07-10 |
PH12017500861A1 (en) | 2017-11-06 |
JP6929771B2 (ja) | 2021-09-01 |
CA2960297A1 (en) | 2016-05-19 |
JP2018500883A (ja) | 2018-01-18 |
PE20170910A1 (es) | 2017-07-12 |
US20210002361A1 (en) | 2021-01-07 |
SG11201703767XA (en) | 2017-06-29 |
US10093730B2 (en) | 2018-10-09 |
US20160168242A1 (en) | 2016-06-16 |
EP3783023A1 (en) | 2021-02-24 |
EP3218403B1 (en) | 2020-05-13 |
US20190092852A1 (en) | 2019-03-28 |
TW201625683A (zh) | 2016-07-16 |
WO2016077381A8 (en) | 2016-06-30 |
CO2017005650A2 (es) | 2017-08-31 |
CR20170240A (es) | 2018-04-03 |
AU2015346460A1 (en) | 2017-03-23 |
IL251248A0 (en) | 2017-05-29 |
US10723795B2 (en) | 2020-07-28 |
EA201791029A1 (ru) | 2017-12-29 |
TWI705976B (zh) | 2020-10-01 |
WO2016077381A1 (en) | 2016-05-19 |
MX2017006094A (es) | 2017-07-19 |
US11725050B2 (en) | 2023-08-15 |
CN107172879B (zh) | 2021-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017009728A2 (pt) | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio | |
BR112017011326A2 (pt) | anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune | |
BR112019003129A2 (pt) | composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer. | |
BR112018005164A2 (pt) | anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer | |
BR112017025564B8 (pt) | Anticorpos anti-ctla-4 e métodos de uso dos mesmos | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
BR112016015958A2 (pt) | Drives de genes guiados pelo rna | |
PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
CO2019006485A2 (es) | Anticuerpos y metodos de su utilizacion | |
AR101845A1 (es) | Anticuerpos anti-her2 e inmunoconjugados | |
MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
BR112018005862A2 (pt) | anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit | |
AR099465A1 (es) | Anticuerpos anti-jagged1 y métodos de uso | |
BR112019012343A2 (pt) | anticorpos il-11ra | |
BR112017020054A2 (pt) | anticorpos para icos | |
BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
UY37523A (es) | Anticuerpos anti-ox40 y sus usos | |
BR112017008914A2 (pt) | método para tratar câncer, composição e uso da composição | |
AR108611A1 (es) | Anticuerpos anti-cd40 y sus usos | |
BR112016010706A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira e método de produção de um anticorpo | |
MX2020003562A (es) | Anticuerpo multiespecifico. | |
AR105187A1 (es) | Aparato, método y sistema para preparación automatizada de explantes y método de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |